certican tablets 0.25 mg
novartis (singapore) pte ltd - everolimus - tablet - 0.25 mg - everolimus 0.25 mg
certican tablets 0.5 mg
novartis (singapore) pte ltd - everolimus - tablet - 0.5 mg - everolimus 0.5 mg
certican tablets 0.75 mg
novartis (singapore) pte ltd - everolimus - tablet - 0.75 mg - everolimus 0.75 mg
certican everolimus 1mg tablet blister pack
novartis pharmaceuticals australia pty ltd - everolimus, quantity: 1 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; lactose monohydrate; hypromellose; magnesium stearate; crospovidone; lactose - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).
certican everolimus 0.75mg tablet blister pack
novartis pharmaceuticals australia pty ltd - everolimus, quantity: 0.75 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; lactose monohydrate; hypromellose; magnesium stearate; crospovidone; lactose - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).
certican everolimus 0.5mg tablet blister pack
novartis pharmaceuticals australia pty ltd - everolimus, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; hypromellose; magnesium stearate; crospovidone; lactose; lactose monohydrate - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).
certican everolimus 0.25mg tablet blister pack
novartis pharmaceuticals australia pty ltd - everolimus, quantity: 0.25 mg - tablet, uncoated - excipient ingredients: butylated hydroxytoluene; lactose monohydrate; hypromellose; magnesium stearate; crospovidone; lactose - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).
certican everolimus 0.25mg dispersible tablet blister pack
novartis pharmaceuticals australia pty ltd - everolimus, quantity: 0.25 mg - tablet, dispersible - excipient ingredients: butylated hydroxytoluene; lactose monohydrate; hypromellose; magnesium stearate; crospovidone; lactose; silicon dioxide - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).
certican everolimus 0.1mg dispersible tablet blister pack
novartis pharmaceuticals australia pty ltd - everolimus, quantity: 0.1 mg - tablet, dispersible - excipient ingredients: butylated hydroxytoluene; lactose monohydrate; hypromellose; magnesium stearate; crospovidone; lactose; silicon dioxide - certican is indicated for the prophylaxis of organ rejection in adult patients at mild to moderate immunological risk receiving an allogeneic renal or cardiac transplant and in adult patients receiving an allogeneic hepatic transplant (see precautions).
certican 0.1mg dispersible tablets
novartis pharmaceuticals uk limited - everolimus 0.1 mg - dispersible tablet